Clinical Trial of Cooling Gel pad for prevention of hand and foot syndrome caused by lyposomal doxorubicine

Clinical Trial of Cooling Gel pad for prevention of hand and foot syndrome caused by lyposomal doxorubicine - CGP for HFS by PLD

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002914

Enrollment

Registered

2009-12-17

Start date

2009-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian cancer

Interventions

PLD alone PLD plus cooling utilizing CGP

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1) To be judged as eligible for PLD treatment by treating physician 2) To be 20 years old or more 3) Life expectancy more than 3 months 4) Written informed consent must be provided

Exclusion criteria

Exclusion criteria: 1) No prior treatment by PLD 2) No existence of HFS

Design outcomes

Primary

Measure	Time frame
Incidence of Grade 2 or more severe HFS	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026